A study has found that PharmaJet’s needle-free injection was superior to needle and syringe for fractional dose poliovirus vaccine campaigns.
The study was designed to assess the feasibility and safety of the Tropis ID injector for administering fIPV in a campaign setting.
PharmaJet Tropis needle-free injector will deliver vaccines intradermally through a narrow and precise fluid stream that distributes the medicine or vaccine into the skin.
Earlier, administration of fractional inactivated poliovirus vaccine (fIPV) via intradermal delivery is said to efficacious and effective in the use of polio vaccine.
The use of a needle and syringe for ID delivery will be slow, technically challenging, inconsistent and painful, making it not suitable for house-to-house campaigns and mass immunizations.
The study showed that Tropis device is safe and effective for the administration of fIPV in a campaign setting.
According to the company, the average preparation and administration time was up to 70% faster compared against needle and syringe, as well as eliminated vaccine wastage.
At present, PharmaJet Tropis device is being used as part of polio eradication efforts in Bangladesh, Cuba, Gambia and Pakistan.
Tropis holds capacity to extract an average of 5.3 doses from each 5 dose vial, enabling to vaccinate 32 more children with the given supply compared to needle and syringe.
PharmaJet chairman and CEO Ron Lowy said: “The PharmaJet Tropis simple point and click design is easy-to-use, and ensures consistent and accurate intradermal injection.
“Additionally, the significantly faster preparation and administration time compared to traditional ID technique with a needle and syringe, makes it an ideal choice for vaccination campaigns.”
Image: PharmaJet’s needle-free injection was superior to needle and syringe for fractional dose poliovirus vaccine campaigns. Photo: courtesy of Baitong333 / FreeDigitalPhotos.net.